MALTOMA
MCID: LYM129
MIFTS: 68

Lymphoma, Mucosa-Associated Lymphoid Type (MALTOMA)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoma, Mucosa-Associated Lymphoid Type

MalaCards integrated aliases for Lymphoma, Mucosa-Associated Lymphoid Type:

Name: Lymphoma, Mucosa-Associated Lymphoid Type 57 73 36
Malt Lymphoma 57 11 58 73 53 5 14 16 75
Mucosa-Associated Lymphoid Tissue Lymphoma 11 58 71
Gastric Lymphoma, Primary 57 73 53
Lymphoma, Malt, Somatic 57 73 38
Extranodal Marginal Zone B-Cell Lymphoma 58 71
Marginal Zone B-Cell Lymphoma 73 71
Maltoma 58 73
Mucosa-Associated Lymphatic Tissue Lymphoma 58
Familial Primary Gastric Lymphoma 71
Primary Gastric Lymphoma 73
Gastric Lymphoma 71

Characteristics:


Inheritance:

Malt Lymphoma: Multigenic/multifactorial 58

Prevelance:

Malt Lymphoma: 1-9/1000000 (Europe) 1-9/100000 (United States, Europe) 58

Age Of Onset:

Malt Lymphoma: Adult 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0050909
OMIM® 57 137245
MeSH 43 D018442
ICD10 via Orphanet 32 C88.4
UMLS via Orphanet 72 C0242647
Orphanet 58 ORPHA52417
MedGen 40 C1850900
UMLS 71 C0242647 C0349532 C1367654 more

Summaries for Lymphoma, Mucosa-Associated Lymphoid Type

UniProtKB/Swiss-Prot: 73 A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary: Lymphoma, Mucosa-Associated Lymphoid Type, also known as malt lymphoma, is related to thyroid lymphoma and burkitt lymphoma. An important gene associated with Lymphoma, Mucosa-Associated Lymphoid Type is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Signal Transduction and Innate Immune System. The drugs Chlorambucil and Tinidazole have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, b cells and thyroid, and related phenotypes are nausea and vomiting and hyperhidrosis

OMIM®: 57 The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT lymphomas are now recognized as a distinct subtype of non-Hodgkin lymphoma (605027). B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) are the most common form of lymphoma arising in extranodal sites, in most cases arising in the gastric mucosa (Isaacson and Spencer, 1995). (137245) (Updated 08-Dec-2022)

Orphanet: 58 MALT (mucosa-associated lymphoid tissue) lymphoma is a rare form of malignant non-Hodgkin lymphoma (see this term) that affects B cells and grows at the expense of lymphoid tissue associated with mucous membranes, but also occurs, more rarely, in lymph nodes.

Disease Ontology: 11 A marginal zone B-cell lymphoma that has material basis in mucosal tissue involved in antibody production.

Wikipedia: 75 MALT lymphoma (MALToma) is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT),... more...

Related Diseases for Lymphoma, Mucosa-Associated Lymphoid Type

Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 722)
# Related Disease Score Top Affiliating Genes
1 thyroid lymphoma 32.4 CD5 BCL6
2 burkitt lymphoma 32.3 IRF4 CXCR5 CXCL13 CD40 BCL6 BCL2
3 lymphoma 32.2 MALT1 IRF4 CXCR5 CXCL13 CD5 CD40
4 b-cell lymphoma 31.9 MALT1 IRF4 IGH FOXP1 CXCR5 CXCL13
5 gastric lymphoma 31.9 S100A8 MALT1 IRF4 CD5 CCR6 BIRC3
6 marginal zone b-cell lymphoma 31.9 S100A8 MALT1 KDM4C IRF4 FOXP1 CD5
7 lymphoma, hodgkin, classic 31.8 TRAF2 KDM4C IRF4 CD40 CCR6 BCL6
8 diffuse large b-cell lymphoma 31.7 KDM4C IRF4 CD5 CCR6 CARD11 BCL6
9 sjogren syndrome 31.6 CXCL13 CD40 CCR6
10 breast lymphoma 31.4 IRF4 CD5 BCL6 BCL2
11 lung lymphoma 31.4 MALT1 IRF4 CD5 BIRC3 BCL6
12 orofaciodigital syndrome viii 31.3 MALT1 KDM4C CD5 BIRC3 BCL6 BCL10
13 lymphoproliferative syndrome 31.3 CD5 CCR6 BCL6 BCL2
14 bladder lymphoma 31.3 CD5 BCL6
15 lymphoma, non-hodgkin, familial 31.3 MALT1 KDM4C IRF4 IGH CXCR5 CD5
16 hashimoto thyroiditis 31.2 CD40 CCR6 BCL2
17 plasmacytoma 31.2 IRF4 IGH CD5 CCND1 BCL2
18 follicular lymphoma 31.1 IRF4 IGH CXCR5 CD5 CD40 CCND1
19 waldenstroem's macroglobulinemia 31.1 IRF4 CD5 CD40 CCND1 BIRC3
20 gastrointestinal lymphoma 31.1 MALT1 CD5 CCND1 BIRC3 BCL6 BCL2
21 monoclonal gammopathy of uncertain significance 31.1 IRF4 CCR6 CCND1
22 gallbladder lymphoma 31.1 MALT1 CD5 BIRC3 BCL6
23 cryoglobulinemia 31.0 CXCL13 CD5 BCL2
24 orbit lymphoma 30.9 MALT1 FOXP1 BCL10
25 intraocular lymphoma 30.9 CXCR5 CXCL13 CD5 BCL6
26 acquired immunodeficiency syndrome 30.9 MADCAM1 CXCR5 CCND1 BCL6 BCL2
27 colon lymphoma 30.9 CD5 CCND1 BCL6 BCL2
28 extramedullary plasmacytoma 30.9 IRF4 CD5 CCND1
29 splenic marginal zone lymphoma 30.9 MALT1 CD5 CCR6 CCND1 CARD11 BIRC3
30 reticulosarcoma 30.9 IGH BCL6 BCL2
31 peripheral t-cell lymphoma 30.8 KDM4C CXCL13 CD5 CCR6 BCL6 BCL2
32 t-cell adult acute lymphocytic leukemia 30.8 IRF4 CD5 CCR6 CARD11
33 small intestine lymphoma 30.8 CD5 BCL6
34 lymphoplasmacytic lymphoma 30.8 IRF4 CD5 CCND1 CARD11 BCL6 BCL2
35 lymphatic system disease 30.8 KDM4C IRF4 CD5 CCR6 BCL6 BCL2
36 leukemia, chronic myeloid 30.8 KDM4C IRF4 CCR6 CCND1 BIRC3 BCL2
37 intravascular large b-cell lymphoma 30.8 BCL6 BCL2
38 angioimmunoblastic t-cell lymphoma 30.8 KDM4C IRF4 CXCR5 CXCL13 CD5 CCR6
39 leukemia, chronic lymphocytic 2 30.8 CD5 BCL2
40 mantle cell lymphoma 30.8 MALT1 KDM4C IRF4 IGH CD5 CD40
41 combined immunodeficiency 30.8 MALT1 IRF4 CD40 CCR6 CARD11 BCL10
42 leukemia, chronic lymphocytic 30.7 KDM4C IRF4 IGH CXCR5 CD5 CD40
43 primary central nervous system lymphoma 30.7 IGH CXCR5 CXCL13 BCL6
44 chronic lymphocytic leukemia/small lymphocytic lymphoma 30.7 CD5 CCND1 BCL6 BCL2
45 leukemia, acute myeloid 30.7 KDM4C CD5 CD40 CCR6 CCND1 BCL6
46 mature b-cell neoplasm 30.7 KDM4C IRF4 CD5 CD40 CCR6 CCND1
47 primary cutaneous t-cell non-hodgkin lymphoma 30.7 KDM4C CD5 CCR6
48 head and neck cancer 30.7 KDM4C CCR6 CCND1 BCL2
49 connective tissue disease 30.7 KDM4C IRF4 CD40 CCR6 CCND1 BCL2
50 lymphangioma 30.6 CCR6 CCND1 BCL2

Graphical network of the top 20 diseases related to Lymphoma, Mucosa-Associated Lymphoid Type:



Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type

Symptoms & Phenotypes for Lymphoma, Mucosa-Associated Lymphoid Type

Human phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

58 30 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002017
2 hyperhidrosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000975
3 fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012378
4 fever 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001945
5 anemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001903
6 weight loss 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001824
7 pulmonary infiltrates 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002113
8 b-cell lymphoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012191
9 constipation 58 30 Frequent (33%) Frequent (79-30%)
HP:0002019
10 recurrent respiratory infections 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002205
11 visual impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000505
12 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002027
13 mediastinal lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100721
14 abnormality of the thyroid gland 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000820
15 abnormal nasolacrimal system morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000614
16 posterior uveitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012123
17 lymphadenopathy 58 Occasional (29-5%)
18 gastric lymphoma 30 HP:0045038

Clinical features from OMIM®:

137245 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.53 BCL10 BIRC3 CARD11 DUSP5
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.53 BCL10 CARD11 DUSP5 CD40
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.53 CD40

MGI Mouse Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 BCL10 BCL2 BCL6 BIRC3 CARD11 CCND1
2 immune system MP:0005387 9.91 BCL10 BCL2 BCL6 BIRC3 CARD11 CCND1
3 hematopoietic system MP:0005397 9.58 BCL10 BCL2 BCL6 BIRC3 CARD11 CCND1

Drugs & Therapeutics for Lymphoma, Mucosa-Associated Lymphoid Type

Drugs for Lymphoma, Mucosa-Associated Lymphoid Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 3 305-03-3 2708
2
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
3 Alkylating Agents Phase 3
4 Antineoplastic Agents, Alkylating Phase 3
5
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613
6
Loperamide Approved Phase 2 53179-11-6 3955
7
Esomeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6, 119141-88-7 9568614 4594
8
Bismuth subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521 16682734
9
Clarithromycin Approved Phase 2 81103-11-9 84029
10
Metronidazole Approved Phase 2 443-48-1, 69198-10-3 4173
11
Tetracycline Approved, Vet_approved, Withdrawn Phase 2 60-54-8 5353990
12
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
13
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
14
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
15
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
16
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
17
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
18
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
19
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
20
Melphalan Approved Phase 2 148-82-3 4053 460612
21
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
22
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
24
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
25
Iodine Approved, Investigational Phase 2 7553-56-2 807
26
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
27
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
28
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
29
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
30
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
31
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
32
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
33
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
35
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
36
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
37
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
38
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
39
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
40
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
41
Busulfan Approved, Investigational Phase 2 55-98-1 2478
42
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
43
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
44
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
45
Oprelvekin Approved, Investigational Phase 1, Phase 2 145941-26-0
46
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
47
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
48
Iron Approved Phase 2 7439-89-6 29936
49
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
50
Brentuximab vedotin Approved, Investigational Phase 1, Phase 2 914088-09-8

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma Unknown status NCT00003617 Phase 3 chlorambucil;clarithromycin;omeprazole;tinidazole
2 Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Completed NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
3 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
4 Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type Unknown status NCT00923663 Phase 2 Lenalidomide
5 A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma Unknown status NCT01678404 Phase 2 131I-rituximab
6 CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA Completed NCT00002682 Phase 2 Amoxicillin;Bismuth Subsalicylate;Clarithromycin;Metronidazole Hydrochloride;Omeprazole;Tetracycline Hydrochloride
7 A Clinico-pathological Phase II Study With Translational Elements to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae With Particular Reference to Chlamydia Species and the Effects of MALT Lymphoma Treatment With Tetracycline Completed NCT01010295 Phase 2 doxycycline (tetracycline)
8 Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Completed NCT01015248 Phase 2 Rituximab and Bendamustine
9 Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma Completed NCT01427114 Phase 2 rituximab, cyclophosphamide, vincristine, and prednisolone
10 Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type Completed NCT00373906 Phase 2 Bortezomib (Velcade)
11 Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Completed NCT00373646 Phase 2 Thalidomide, Pharmion
12 A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00117156 Phase 2 Fludarabine;Rituximab
13 Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone Completed NCT01514344 Phase 2 intralesional rituximab
14 Radiation Therapy Alone for Stage 1 and 2 MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma Completed NCT04465162 Phase 2
15 Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142) Completed NCT00210327 Phase 2 Bortezomib (drug)
16 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
17 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
18 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
19 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
20 A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas Completed NCT02254772 Phase 1, Phase 2 SD-101
21 Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma Completed NCT01682044 Phase 2
22 A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2 cyclophosphamide;etoposide
23 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
24 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
25 Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma Completed NCT00026182 Phase 2
26 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
27 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
28 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
29 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
30 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
31 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
32 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
33 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
34 A Phase II Study of CCI-779 in B-cell Lymphoma and CLL Completed NCT00290472 Phase 2 temsirolimus
35 Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma Completed NCT00244855 Phase 2 dexamethasone
36 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
37 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
38 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
39 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
40 A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant Completed NCT00058305 Phase 2 bryostatin 1;vincristine sulfate
41 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
42 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
43 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed NCT01261247 Phase 2 panobinostat
44 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
45 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
46 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
47 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
48 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
49 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
50 A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma Completed NCT01068392 Phase 2 Oxaliplatin, Prednisolone

Search NIH Clinical Center for Lymphoma, Mucosa-Associated Lymphoid Type

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Lymphoma, Mucosa-Associated Lymphoid Type:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Mucosa-Associated Lymphoid Type:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Lymphoma, Mucosa-Associated Lymphoid Type

Anatomical Context for Lymphoma, Mucosa-Associated Lymphoid Type

Organs/tissues related to Lymphoma, Mucosa-Associated Lymphoid Type:

MalaCards : Salivary Gland, B Cells, Thyroid, Thymus, Breast, Lung, Bone Marrow

Publications for Lymphoma, Mucosa-Associated Lymphoid Type

Articles related to Lymphoma, Mucosa-Associated Lymphoid Type:

(show top 50) (show all 5545)
# Title Authors PMID Year
1
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 53 62 57 5
9989495 1999
2
The biology of low grade MALT lymphoma. 62 57
7629280 1995
3
Familial primary gastric lymphoma. 62 57
8432445 1993
4
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 5
10408400 1999
5
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 5
10380920 1999
6
Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. 57
6193858 1983
7
Regression of rectal mucosa-associated lymphoid tissue (MALT) lymphoma after antibiotic treatments. 53 62
20518898 2010
8
Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. 53 62
19714753 2010
9
The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. 53 62
19965626 2010
10
Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. 53 62
20302630 2010
11
Primary mucosa-associated lymphoid tissue lymphoma of the gallbladder: report of a case harboring API2/MALT1 gene fusion. 53 62
19535128 2009
12
Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. 53 62
19525185 2009
13
Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma. 53 62
19385974 2009
14
Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma. 53 62
19279678 2009
15
BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. 53 62
18949449 2008
16
[Primary ocular adnexal lymphoproliferative lesions: clinicopathologic features and genetic alterations]. 53 62
19159526 2008
17
Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. 53 62
19189651 2008
18
Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. 53 62
18628489 2008
19
[Frequency of genetic aberrations in mucosa-associated lymphoid tissue lymphoma of different sites]. 53 62
19094584 2008
20
Significance of CXCR3 expression in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication. 53 62
18616679 2008
21
Influence of Helicobacter pylori infection persistence on bcl-2 expression in gastric mucosa inflammatory cells. 53 62
19175059 2008
22
Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas. 53 62
18561120 2008
23
Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. 53 62
18445693 2008
24
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. 53 62
18354239 2008
25
Chromosomal instability in gastric mucosa-associated lymphoid tissue lymphomas: a fluorescent in situ hybridization study using a tissue microarray approach. 53 62
18234275 2008
26
T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. 53 62
18223652 2008
27
Chromosomal translocations involving BCL6 in MALT lymphoma. 53 62
18166802 2008
28
[Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type]. 53 62
18346354 2007
29
Generation of a new monoclonal antibody against MALT1 by genetic immunization. 53 62
17451356 2007
30
Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. 53 62
17167822 2007
31
CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma. 53 62
17300675 2007
32
MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas. 53 62
17199743 2007
33
Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10. 53 62
17213322 2007
34
Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. 53 62
17222250 2007
35
Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. 53 62
16980947 2006
36
The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. 53 62
17122510 2006
37
MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. 53 62
16917511 2006
38
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. 53 62
16772602 2006
39
Functional polymorphisms of CD14 and toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. 53 62
17086894 2006
40
Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma. 53 62
16784987 2006
41
Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein. 53 62
16572204 2006
42
Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). 53 62
16512826 2006
43
Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twenty-six cases with malignant lymphoma of small intestine. 53 62
16484127 2006
44
MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells. 53 62
16341151 2006
45
Frequency of chromosomal aneuploidies and deletions of the RB and TP53 genes in MALT lymphomas harboring the t(14;18)(q32;q21). 53 62
16364768 2006
46
A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. 53 62
16280327 2006
47
[Expression of bcl-10 protein in MALT lymphoma]. 53 62
16545185 2005
48
Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma. 53 62
16177990 2005
49
BCL10 expression in ocular adnexal lymphomas. 53 62
16310461 2005
50
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). 53 62
15845895 2005

Variations for Lymphoma, Mucosa-Associated Lymphoid Type

ClinVar genetic disease variations for Lymphoma, Mucosa-Associated Lymphoid Type:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs) DUP Pathogenic
6250 rs387906350 GRCh37: 1:85733512-85733513
GRCh38: 1:85267829-85267830
2 BCL10 NM_003921.5(BCL10):c.163dup (p.Ile55fs) DUP Pathogenic
6251 rs587776630 GRCh37: 1:85736483-85736484
GRCh38: 1:85270800-85270801
3 BCL10 NM_003921.5(BCL10):c.345del (p.Gly116fs) DEL Pathogenic
6252 rs587776631 GRCh37: 1:85736302-85736302
GRCh38: 1:85270619-85270619

Copy number variations for Lymphoma, Mucosa-Associated Lymphoid Type from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 119732 18 16100000 76117153 Gain MALT1 Mucosa-associated lymphoid tissue lymphomas
2 206010 6 135101251 139048099 Loss TNFAIP3 Mucosa-associated lymphoid tissue lymphomas

Expression for Lymphoma, Mucosa-Associated Lymphoid Type

LifeMap Discovery
Genes differentially expressed in tissues of Lymphoma, Mucosa-Associated Lymphoid Type patients vs. healthy controls: 35 (show all 26)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 APOA4 apolipoprotein A4 Stomach - 6.08 0.008
2 DEFA5 defensin alpha 5 Stomach - 5.85 0.050
3 ZG16 zymogen granule protein 16 Stomach - 5.41 0.020
4 RBP2 retinol binding protein 2 Stomach - 5.33 0.041
5 SPINK4 serine peptidase inhibitor Kazal type 4 Stomach - 5.25 0.028
6 APOC3 apolipoprotein C3 Stomach - 5.22 0.020
7 ALDOB aldolase, fructose-bisphosphate B Stomach - 5.12 0.000
8 C17orf78 chromosome 17 open reading frame 78 Stomach - 4.64 0.025
9 PCK1 phosphoenolpyruvate carboxykinase 1 Stomach - 4.50 0.007
10 ITLN2 intelectin 2 Stomach - 4.46 0.024
11 C3orf85 chromosome 3 open reading frame 85 Stomach - 4.36 0.046
12 APOA1 apolipoprotein A1 Stomach - 4.13 0.012
13 S100G S100 calcium binding protein G Stomach - 4.13 0.016
14 ITLN1 intelectin 1 Stomach - 4.03 0.013
15 SLC3A1 solute carrier family 3 member 1 Stomach - 3.96 0.006
16 CPS1 carbamoyl-phosphate synthase 1 Stomach - 3.90 0.050
17 ERICH4 glutamate rich 4 Stomach - 3.87 0.039
18 SLC17A4 solute carrier family 17 member 4 Stomach - 3.72 0.028
19 SLC7A9 solute carrier family 7 member 9 Stomach - 3.71 0.029
20 OTC ornithine transcarbamylase Stomach - 3.70 0.034
21 TMPRSS15 transmembrane serine protease 15 Stomach - 3.58 0.042
22 FABP1 fatty acid binding protein 1 Stomach - 3.51 0.032
23 CASP16P caspase 16, pseudogene Stomach - 3.49 0.003
24 CREB3L3 cAMP responsive element binding protein 3 like 3 Stomach - 3.44 0.039
25 MEP1B meprin A subunit beta Stomach - 3.38 0.041
26 SLC2A2 solute carrier family 2 member 2 Stomach - 3.08 0.012
Search GEO for disease gene expression data for Lymphoma, Mucosa-Associated Lymphoid Type.

Pathways for Lymphoma, Mucosa-Associated Lymphoid Type

Pathways related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 13.62 BCL2 BIRC3 CCND1 CCR6 CXCL13 CXCR5
2
Show member pathways
13.32 TRAF2 S100A8 MALT1 MADCAM1 IRF4 CD40
3
Show member pathways
13.28 TRAF2 CXCR5 CXCL13 CD40 CCR6 CCND1
4
Show member pathways
13.19 BCL2 BCL6 BIRC3 CCND1 CD40 IRF4
5
Show member pathways
12.57 TRAF2 MALT1 CD40 CARD11 BCL10
6
Show member pathways
12.15 TRAF2 MALT1 BIRC3 BCL2 BCL10
7
Show member pathways
12.11 MALT1 CD40 CARD11 BCL10
8
Show member pathways
12.01 MALT1 CCND1 CARD11 BCL10
9 11.92 S100A8 IRF4 CD40 CCND1 BCL6
10 11.8 CCND1 BCL6 BCL2
11 11.79 IRF4 CCND1 BCL6 BCL2
12 11.78 CCND1 BCL6 BCL2
13 11.74 CXCR5 CXCL13 CD40
14 11.72 TRAF2 CCND1 BIRC3 BCL2
15 11.68 TRAF2 MALT1 IRF4 CXCR5 CARD11 BCL6
16 11.66 IRF4 CXCR5 CCR6
17 11.66 CCND1 BIRC3 BCL2
18
Show member pathways
11.53 TRAF2 CD40 BIRC3 BCL2
19 11.49 DUSP5 CCND1 BCL2
20 11.47 BCL6 CD40 CXCR5 IRF4
21 11.4 MALT1 CD40 CARD11 BCL10
22 11.27 MALT1 CARD11 BCL6 BCL10
23 11.1 TRAF2 CD40 BIRC3
24 10.87 CD40 CCR6

GO Terms for Lymphoma, Mucosa-Associated Lymphoid Type

Cellular components related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polkadots GO:0002096 9.26 MALT1 BCL10
2 CBM complex GO:0032449 9.1 MALT1 CARD11 BCL10

Biological processes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 10.07 BCL10 BCL2 BIRC3 CARD11 MALT1 TRAF2
2 immune system process GO:0002376 10.03 S100A8 MALT1 IRF4 CD40 CARD11 BCL6
3 regulation of inflammatory response GO:0050727 10 S100A8 FOXP1 BIRC3 BCL6
4 B cell activation GO:0042113 9.97 MALT1 CXCR5 CD40
5 chemotaxis GO:0006935 9.96 S100A8 CXCR5 CXCL13 CCR6
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.93 BCL10 BIRC3 CARD11 CD40 MALT1 TRAF2
7 B cell proliferation GO:0042100 9.92 CD40 CARD11 BCL6 BCL2
8 negative regulation of B cell apoptotic process GO:0002903 9.88 FOXP1 BCL6 BCL2
9 chronic inflammatory response GO:0002544 9.87 S100A8 CXCL13
10 positive regulation of B cell proliferation GO:0030890 9.86 CD40 CARD11 BCL6 BCL2
11 regulation of immune response GO:0050776 9.85 CD40 CARD11 BCL6
12 positive regulation of T cell activation GO:0050870 9.78 BCL10 CARD11 MALT1
13 regulation of immunoglobulin production GO:0002637 9.75 TRAF2 CD40
14 response to fungus GO:0009620 9.7 MALT1 BCL10
15 regulation of T cell receptor signaling pathway GO:0050856 9.69 MALT1 BCL10
16 positive regulation of interleukin-2 production GO:0032743 9.56 TRAF2 MALT1 IRF4 CARD11
17 regulation of programmed cell death GO:0043067 9.54 BIRC3 BCL2
18 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.4 TRAF2 S100A8 MALT1 CD40 CARD11 BCL10

Molecular functions related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activator activity GO:0019209 9.26 MALT1 BCL10
2 protein self-association GO:0043621 9.23 MALT1 FOXP1 CARD11 BCL10

Sources for Lymphoma, Mucosa-Associated Lymphoid Type

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....